ArticleBiochemical genetics2026
TRPV4 is Associated with a Marfan Syndrome-Related Mechanosensitive Gene Program in Aortic Smooth Muscle Cells.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Marfan syndrome (MFS) aortopathy involves extracellular matrix disruption, altered mechanical cues, and maladaptive vascular smooth muscle cell (VSMC) remodeling. However, the mechanosensitive regulators associated with MFS-related VSMC dysfunction remain unclear. This study aimed to identify and validate mechanosensitive candidate genes in MFS aortopathy. Public VSMC transcriptomic data from GSE128101 were re-analyzed to identify differentially expressed genes (DEGs). Protein-protein interaction analysis, functional enrichment, and minimum redundancy maximum relevance analysis were used to prioritize mechanosensitive candidates. Candidate genes were examined in independent MFS-related datasets and validated by qRT-PCR in primary aortic medial VSMCs from MFS patients and donor controls. TRPV4 localization was assessed by immunofluorescence. TRPV4 function was evaluated in primary human aortic smooth muscle cells using overexpression and siRNA-mediated knockdown, followed by proliferation, wound-closure, inflammatory cytokine, and NF-κB pathway assays. A total of 436 DEGs were identified in MFS-derived aortic VSMCs. Functional analyses highlighted extracellular matrix remodeling, mechanotransduction-related, inflammatory, and cytoskeleton-associated pathways. TRPV4 was the top-ranked mechanosensitive candidate, with TRPM5 also identified as an overlapping candidate. qRT-PCR confirmed increased TRPV4 and TRPM5 expression in MFS-derived VSMCs. MFS-derived VSMCs also showed elevated inflammatory gene expression and enhanced membrane-associated TRPV4 localization. In vitro, TRPV4 overexpression promoted proliferation, wound closure, inflammatory cytokine secretion, and NF-κB pathway phosphorylation, whereas TRPV4 knockdown showed opposite effects. These exploratory findings identify TRPV4 as a leading mechanosensitive candidate associated with MFS-related VSMC remodeling and inflammatory activation. Larger cohorts, MFS-specific models, and direct mechanistic assays are required to determine its biomarker or therapeutic relevance.
Indexed as
Identifiers
42747764What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.